We are happy to announce that we have added 17 new gene panels to our Spotlight line of tests. These new tests will expand our menu by 65%, offering new testing options in neurology, endocrinology, epilepsy, developmental delay, mitochondrial disease, and other disease areas.
Courtagen’s Spotlight™ panels provide a targeted approach to genetic testing when a patient's symptomology is discernible. Each panel contains between approximately 3 to 50 genes selected to address a group of disorders with overlapping symptoms, making test selection clear and straightforward.
Expanding our Spotlight tests is an important area of focus for Courtagen this year. In addition to adding new neurology tests, we are also moving into adjacent disease areas to address the overlapping symptoms we see in our patient population. For example, the new Spotlight tests include several pain-related panels, such as migraine, neuropathic pain, and abdominal pain. We have also expanded into endocrinology-related panels including hyper/hypoglycemia (MODY+), hyperparathyroidism, and pituitary hormone deficiency. Finally, our new neurology panels target neuromuscular disorders, such as periodic paralysis, dystonia, and rhabdomyolysis.
We hope that offering smaller Spotlight tests will provide a way for physicians to target the most clinically relevant genes for the symptoms displayed by their patients. With that said, we will continue to offer our comprehensive panels for a reflex option or for patients with more complex and heterogeneous symptoms.
Stay tuned for more updates to our testing menu!